Q-omics provides the consensus-scored DCLK3 profile across patient tissues and cancer cell-line models. DCLK3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DCLK3 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, DCLK3 RNA expression shows 14,945 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where DCLK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCLK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCLK3 survival associations across molecular data types. DCLK3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCLK3 RNA expression–survival associations across cancer types. High DCLK3 expression shows unfavorable associations in KIRP, STAD, BRCA, MESO, UVM and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DCLK3 RNA expression.
This table summarizes DCLK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DCLK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCLK3 shows higher tumor expression in KIRC, STAD, HNSC, COAD, LIHC and BRCA. The KIRC box plot shows higher DCLK3 RNA expression in tumor versus normal tissue (log2 FC = +0.616, t-test p < 0.001).
This table shows molecular features associated with DCLK3 in patient tissues and cancer cell lines. In patient samples, DCLK3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DCLK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_SCLC.
